<qa>  What is the MTD determined in phase I?- Phase II colorectal cancer patients: Patients receive capecitabine at the MTD determined in phase I in combination with irinotecan hydrochloride during odd-numbered courses and oxaliplatin during even-numbered courses as in phase I. Patients also receive bevacizumab IV over 30-90 minutes on days 1 and 15 of each course. 